KLOW Stack (GHK-Cu, BPC-157, TB-500, and KPV)

What Is the KLOW Stack?

The KLOW Stack builds on the three-peptide Glow Stack (GHK-Cu, BPC-157, and TB-500) by adding a fourth compound, KPV, the "K" in the name. Each of the four peptides carries a distinct research focus: GHK-Cu is a naturally occurring copper-binding peptide studied for collagen production and skin structure; BPC-157 is a peptide originally identified in the stomach, studied for blood vessel formation and gut-related signaling; TB-500 is a fragment of Thymosin Beta-4 studied for its role in cell migration; and KPV is a fragment of alpha-MSH studied for calming inflammatory signaling.

Because each peptide's research base sits at a different angle of tissue health, structural building, blood flow, cell movement, and inflammation control, researchers combining all four are generally interested in whether addressing each angle together produces a more complete picture than any single peptide alone. The large majority of published research studies each of these four peptides individually rather than as a combined four-part stack.

What This Stack Is Being Researched For

• Skin Structure and Collagen

  GHK-Cu's research base centers on collagen production and the enzymes involved in maintaining connective tissue structure.^[1]

• Tissue and Blood Vessel Support

  BPC-157's research base centers on blood vessel formation and gut-related signaling, both tied to how tissue receives blood flow and structural support.^[2][3]

• Cell Migration

  TB-500's research base centers on actin, the protein that lets cells move and change shape, making it a subject of research in wound closure and directed cell movement.^[4]

• Calming Inflammatory Signaling

  KPV's research base centers on reducing inflammatory signaling pathways, with a particular research history in gut and skin inflammation models.^[5][6]

How the Stack Works

• GHK-Cu and Collagen Support

  Research points to GHK-Cu delivering copper to enzymes involved in cross-linking collagen fibers, while signaling skin cells to increase production of structural proteins that support skin's underlying framework.^[1]

• BPC-157 and Blood Flow

  Research points to BPC-157 affecting new blood vessel formation and nitric oxide signaling, both of which relate to how well blood reaches an area of tissue.^[2][3]

• TB-500 and Cell Movement

  Research points to TB-500 interacting with actin to help direct the movement of cells like fibroblasts toward an area, a process relevant to how tissue closes and rebuilds after injury.^[4]

• KPV and Inflammation Control

  Research points to KPV blocking NF-kB, a signaling pathway heavily involved in triggering inflammation, doing so without activating the classical hormone receptors its parent molecule, alpha-MSH, uses.^[5][6]

• Why the Four Are Paired

  Since each peptide's research base sits at a different stage of tissue health, structural building, blood flow, cell movement, and inflammation control, researchers combining all four are generally interested in whether addressing each angle together supports a more complete picture than any single peptide alone.

Reconstitution and Handling

All four peptides are typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out for each peptide separately before mixing. Once reconstituted, all four solutions are kept refrigerated to help preserve stability.

Key Takeaways

The KLOW Stack brings together four peptides with genuinely different research focuses rather than four versions of the same mechanism: GHK-Cu for structural skin support, BPC-157 for blood vessel formation, TB-500 for cell movement, and KPV for inflammation control. Most of what's published studies each one separately, with GHK-Cu carrying the most human-relevant research history of the four. Treat the combination as a research-community practice built on complementary mechanisms rather than an established body of combined-use evidence.

Frequently Asked Questions

Sources and Research

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987.
2. Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768-777.
3. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.
4. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105.
5. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003;306(2):631-637.
6. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.